Board and management exercises warrants of series TO 2
Initiator Pharma A/S (“Initiator Pharma” or “the Company”) exercise period for warrants of series TO 2 (“TO 2”) is currently ongoing and it ends on Tuesday, December 15, 2020. The Company can today announce that members of the Board and management has exercised TO 2 for a total amount corresponding to approximately SEK 0.5 million. Among those who have exercised their TO 2 are, among others, the Company's CEO Claus Olesen and chairman Magnus Persson.TO 2 was issued in connection with the Company's rights issue of units and directed issue of units in June 2020. The capital the Company can be